

Marta Āukaszewicz-ZajÄc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2483678/publications.pdf>

Version: 2024-02-01

43
papers

914
citations

471371
17
h-index

501076
28
g-index

44
all docs

44
docs citations

44
times ranked

1135
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitisation and allergic reactions to alpha-1,3-galactose in Podlasie, Poland, an area endemic for tick-borne infections. <i>Infectious Diseases</i> , 2022, 54, 572-579.	1.4	5
2	Granzymes – Their Role in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5277.	1.8	5
3	A Disintegrin and Metalloproteinase (ADAM) Family – Novel Biomarkers of Selected Gastrointestinal (GI) Malignancies?. <i>Cancers</i> , 2022, 14, 2307.	1.7	7
4	The Clinical Utility of Serum CXCR-2 Assessment in Colorectal Cancer (CRC) Patients. <i>Anticancer Research</i> , 2021, 41, 1421-1428.	0.5	5
5	Circulating Biomarkers of Colorectal Cancer (CRC) – Their Utility in Diagnosis and Prognosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2391.	1.0	22
6	A Disintegrin and Metalloproteinase (ADAM) Family: Their Significance in Malignant Tumors of the Central Nervous System (CNS). <i>International Journal of Molecular Sciences</i> , 2021, 22, 10378.	1.8	11
7	Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer. <i>Cancers</i> , 2021, 13, 5186.	1.7	12
8	<p>The Significance of CXCL1 and CXCL8 as Well as Their Specific Receptors in Colorectal Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 8435-8443.	0.9	24
9	The Role of Chemokines in the Development of Gastric Cancer – Diagnostic and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8456.	1.8	16
10	Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6193.	1.8	3
11	Clinical significance of fluid biomarkers in Alzheimer – TM's Disease. <i>Pharmacological Reports</i> , 2020, 72, 528-542.	1.5	22
12	The significance of chemokine CXCL-8 in esophageal carcinoma. <i>Archives of Medical Science</i> , 2020, 16, 475-480.	0.4	9
13	CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2040.	1.8	29
14	Chemokines – What Is Their Role in Colorectal Cancer?. <i>Cancer Control</i> , 2020, 27, 107327482090338.	0.7	15
15	Clinical Significance of Selected Chemokines in Thyroid Cancer. <i>Anticancer Research</i> , 2019, 39, 2715-2720.	0.5	4
16	Novel potential biomarkers for pancreatic cancer – A systematic review. <i>Advances in Medical Sciences</i> , 2019, 64, 252-257.	0.9	9
17	Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients. <i>Clinical and Experimental Medicine</i> , 2019, 19, 191-199.	1.9	23
18	Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC). <i>Oncotarget</i> , 2019, 10, 395-403.	0.8	10

#	ARTICLE	IF	CITATIONS
19	The impact of laparoscopic adrenalectomy on renal function. Results of a prospective randomised clinical trial. <i>Endokrynologia Polska</i> , 2019, 70, 409-416.	0.3	4
20	The role of selected chemokines and their specific receptors in pancreatic cancer. <i>International Journal of Biological Markers</i> , 2018, 33, 141-147.	0.7	12
21	Serum chemokine CXCL-8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR-2, CRP and classical tumor markers (CA 19-9 and CEA). <i>Polish Archives of Internal Medicine</i> , 2018, 128, 524-531.	0.3	15
22	Stem cell factor in the serum of patients with esophageal cancer in relation to its histological types. <i>Archives of Medical Science</i> , 2017, 6, 1357-1364.	0.4	3
23	The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer. <i>Disease Markers</i> , 2016, 2016, 1-7.	0.6	28
24	Matrix Metalloproteinases and Their Tissue Inhibitors in Comparison to Other Inflammatory Proteins in Gastric Cancer (GC). <i>Cancer Investigation</i> , 2016, 34, 305-312.	0.6	16
25	Serum concentrations of receptor for interleukin 8 in patients with esophageal cancer. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 854-861.	0.3	6
26	Chemokines and their receptors in esophageal cancerâ€”the systematic review and future perspectives. <i>Tumor Biology</i> , 2015, 36, 5707-5714.	0.8	20
27	Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS). <i>Journal of Neural Transmission</i> , 2014, 121, 1387-1397.	1.4	23
28	Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS). <i>Journal of Neural Transmission</i> , 2014, 121, 469-477.	1.4	9
29	Comparative Evaluation of Serum <sc>C</sc>â€™Reactive Protein (<sc>CRP</sc>) Levels in the Different Histological Subtypes of Esophageal Cancer (Squamous Cell Carcinoma and Tj ETQq1 1 0.784314 rgBT /Ove lock 10 Tf 50 13		
30	Cerebrospinal fluid leakageâ€™Reliable diagnostic methods. <i>Clinica Chimica Acta</i> , 2011, 412, 837-840.	0.5	69
31	Gastric cancer â€™ The role of matrix metalloproteinases in tumor progression. <i>Clinica Chimica Acta</i> , 2011, 412, 1725-1730.	0.5	57
32	Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. <i>Clinical and Experimental Medicine</i> , 2011, 11, 89-96.	1.9	57
33	Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. <i>Folia Histochemica Et Cytobiologica</i> , 2011, 49, 125-131.	0.6	21
34	Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1467-1473.	1.4	19
35	Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue.. <i>Folia Histochemica Et Cytobiologica</i> , 2010, 47, 511-6.	0.6	15
36	Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in gastric cancer.. <i>Folia Histochemica Et Cytobiologica</i> , 2010, 47, 491-6.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1133-9.	1.4	29
38	Clinical Significance of the Measurements of Serum Matrix Metalloproteinase-9 and Its Inhibitor (Tissue Inhibitor of Metalloproteinase-1) in Patients With Pancreatic Cancer. <i>Pancreas</i> , 2009, 38, 613-618.	0.5	56
39	Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer.. <i>Folia Histochemica Et Cytobiologica</i> , 2009, 46, 471-8.	0.6	11
40	Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma. , 2009, 119, 558-63.		7
41	The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. <i>Clinica Chimica Acta</i> , 2008, 389, 61-66.	0.5	83
42	Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1423-8.	1.4	80
43	The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. <i>Clinica Chimica Acta</i> , 2006, 374, 165-167.	0.5	12